Sivia Capital Partners LLC Has $474,000 Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Sivia Capital Partners LLC boosted its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 16.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,227 shares of the company’s stock after purchasing an additional 889 shares during the period. Sivia Capital Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $474,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Schroder Investment Management Group raised its position in Dr. Reddy’s Laboratories by 77.6% in the 4th quarter. Schroder Investment Management Group now owns 266,653 shares of the company’s stock valued at $18,554,000 after buying an additional 116,488 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 126.5% in the fourth quarter. Fisher Asset Management LLC now owns 205,280 shares of the company’s stock valued at $14,283,000 after purchasing an additional 114,630 shares during the last quarter. National Bank of Canada FI lifted its position in shares of Dr. Reddy’s Laboratories by 81.6% in the second quarter. National Bank of Canada FI now owns 184,120 shares of the company’s stock worth $13,884,000 after purchasing an additional 82,724 shares in the last quarter. Panagora Asset Management Inc. boosted its holdings in Dr. Reddy’s Laboratories by 20.8% during the second quarter. Panagora Asset Management Inc. now owns 151,841 shares of the company’s stock worth $11,569,000 after purchasing an additional 26,165 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Dr. Reddy’s Laboratories by 2.3% in the fourth quarter. Wellington Management Group LLP now owns 144,445 shares of the company’s stock valued at $10,050,000 after purchasing an additional 3,291 shares in the last quarter. Institutional investors and hedge funds own 14.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on RDY. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 16th. Barclays upped their target price on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $79.20 on Friday. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $80.77 and its 200 day simple moving average is $75.53. Dr. Reddy’s Laboratories Limited has a 1-year low of $63.72 and a 1-year high of $84.46. The company has a market cap of $13.22 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 1.84 and a beta of 0.55.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The firm had revenue of $919.80 million during the quarter, compared to the consensus estimate of $861.68 million. On average, research analysts forecast that Dr. Reddy’s Laboratories Limited will post 4.11 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.